Man Group PLC Sutro Biopharma, Inc. Transaction History

Man Group PLC

$36 Billion
Q3 2024

A detailed history of Man Group PLC transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Man Group PLC holds 163,928 shares of STRO stock, worth $301,627. This represents 0.0% of its overall portfolio holdings.

Number of Shares

163,928

Previous 130,277 25.83%

Holding current value

$301,627

Previous $381,000 48.82%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.88 - $5.01 $96,914 - $168,591	33,651 Added 25.83%	163,928 $567,000
Q2 2024 Aug 14, 2024	SELL	$2.92 - $5.33 $176,239 - $321,697	-60,356 Reduced 31.66%	130,277 $381,000
Q1 2024 May 15, 2024	BUY	$3.27 - $5.65 $233,952 - $404,229	71,545 Added 60.08%	190,633 $1.08 Million
Q4 2023 Feb 14, 2024	BUY	$2.07 - $4.54 $35,763 - $78,437	17,277 Added 16.97%	119,088 $510,000
Q3 2023 Nov 14, 2023	SELL	$3.29 - $4.9 $483,149 - $719,584	-146,854 Reduced 59.06%	101,811 $353,000
Q2 2023 Aug 14, 2023	BUY	$4.25 - $5.88 $98,629 - $136,457	23,207 Added 10.29%	248,665 $1.16 Million
Q1 2023 May 15, 2023	BUY	$4.48 - $8.45 $40,382 - $76,168	9,014 Added 4.16%	225,458 $1.04 Million
Q4 2022 Feb 14, 2023	BUY	$5.41 - $8.08 $266,507 - $398,036	49,262 Added 29.47%	216,444 $1.75 Million
Q3 2022 Nov 14, 2022	SELL	$5.17 - $7.11 $10,133 - $13,935	-1,960 Reduced 1.16%	167,182 $928,000
Q2 2022 Aug 15, 2022	BUY	$3.41 - $8.95 $431,845 - $1.13 Million	126,641 Added 297.97%	169,142 $881,000
Q1 2022 May 16, 2022	BUY	$7.78 - $15.31 $330,657 - $650,690	42,501 New	42,501 $349,000

Others Institutions Holding STRO

# of Institutions

137

Shares Held

62.4M

Call Options Held

77.1K

Put Options Held

31.4K

View Full List

About SUTRO BIOPHARMA, INC.

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $96M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

More about STRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account